Dear Friends and Supporters,
Going into 2017, Oracle continues to be at the forefront of funding pioneering research into head and neck cancer. Cases of head and neck cancer are growing at an alarming rate, and with cases of oral cancer up by 90% our work is more vital than ever. We currently fund a range of exciting and varied projects that include immuno and virus therapies, studies into radiotherapy, combination therapies, and drug development.
Over the past ten years, Oracle has invested over £5m into our research programmes discovering these new and improved treatments. Oracle’s vision is to continue to focus on funding early-stage research and proof-of-concept projects. Thanks to the continued generosity of our supporters, we are still the UK’s leading funder of these pioneering research studies that simply would not happy without your continued support. Over the past year, our supporters have contributed to our funding through donating,, participating in challenge events and hosting their own fundraising events.
We have a number of events in 2017 including our popular golf day on the 28th September, our annual research event on the 10th October and our 11th Glory of Christmas Concert in December. We look forward to seeing you at one of our events, and thank you for your ongoing support.
With best wishes,
Peter Rhys Evans
Chairman and Founder